Anatomic Suitability for Present and Next Generation Transcatheter Aortic Valve Prostheses Evidence for a Complementary Multidevice Approach to Treatment by Jilaihawi, Hasan et al.
A
G
E
H
R
M
O
c
B
s
(
e
t
M
e
T
b
r
w
P
R
S
c
a
s
w
C
p
C
F
B
G
1
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 8 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 0 5 . 0 1 5natomic Suitability for Present and Next
eneration Transcatheter Aortic Valve Prostheses
vidence for a Complementary Multidevice Approach to Treatment
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éda Ibrahim, MD,* Tomasz Spyt, MD,† Derek Chin, MBBS,† Jan Kovac, MD†
ontreal, Quebec, Canada; and Leicester, United Kingdom
bjectives This study sought to assess the proportion of patients anatomically suitable for trans-
atheter aortic valve implantation by multiple access approaches.
ackground The devices currently in mainstream use for transcatheter treatment of severe aortic
tenosis are those of Edwards (Edwards Lifesciences, Nyon, Switzerland) and Medtronic CoreValve
M-C) (Luxembourg City, Luxembourg). The range of patients that these can presently treat requires
lucidation to guide the necessary evolution of these technologies and increase their scope of
herapy.
ethods A consecutive series of patients were assessed with transthoracic or transesophageal
chocardiography and invasive angiography to assess anatomical suitability by different approaches.
he transfemoral access requirements for Edwards and M-C (Edwards currently 22- and 24-F, soon to
e 18- and 19-F; M-C 18-F) as well as the aortic valve annular criteria (18 to 25 mm and 20 to 27 mm,
espectively) were incorporated in this assessment. Patients unsuitable for the transfemoral approach
ere considered for Edwards transapical and M-C transaxillary and direct ascending aortic access.
atients suitable for these devices and access approaches were identiﬁed.
esults Data were analyzed for 100 consecutive patients. Edwards suitability was 28% for Edwards-
apien transfemoral, 78% for Edwards Novaﬂex transfemoral, and 88% for Edwards-Sapien transapi-
al. Medtronic CoreValve suitability was 84% for transfemoral and 89% using additional transaxillary
nd direct aortic approaches. Of the 12 patients unsuitable for Edwards-based procedures, 8 were
uitable for M-C. Of the 11 patients unsuitable for M-C–based techniques, 8 were suitable for Ed-
ards. Only 3% were anatomically unsuitable for all approaches.
onclusions In this series, 97% of patients were anatomically suitable for a complementary ap-
roach to treatment. (J Am Coll Cardiol Intv 2010;3:859–66) © 2010 by the American College of
ardiology Foundation
rom the *Montreal Heart Institute, Montreal, Quebec, Canada; and the †Glenfield Hospital, Leicester, United Kingdom. Dr.
onan has received honoraria and is a consultant for Medtronic CoreValve. Dr. Asgar is a Consultant Honoraria ($10,000) for
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860ranscatheter aortic valve implantation (TAVI) has
chieved great success in treating high-risk and inopera-
le patients with severe aortic stenosis (1– 8). The 2
evices in mainstream use (post-CE mark) in Europe are
he Medtronic CoreValve (Luxembourg City, Luxem-
ourg) (3) and the Edwards Sapien (Edwards Life-
ciences, Nyon, Switzerland) (6) devices, accounting for
ver 12,000 implants to-date worldwide. However, ana-
omical constraints remain, in particular with peripheral
rterial access for transfemoral approaches and aortic
alve annular dimensions for all approaches. The impact
See page 867
f these constraints on the treatment offered to a range of
atients is unknown; the magnitude and nature of the
mpact may guide further evolution of technology, allowing
hysicians to offer safe therapy to the wider pool of patients
ith aortic stenosis who are not treated (9). In a 2-center
eries of consecutive patients assessed for TAVI, we there-
ore determined the proportion of patients anatomically
uitable for treatment by the multiple approaches available.
e evaluated this using selection criteria for present devices
nd those for imminent next-generation devices. We hy-
pothesized that a greater propor-
tion of patients could be treated
if both device types and all ap-
proaches were available in the
selection process.
ethods
atient assessment. A consecutive series of 100 patients
ere assessed in 2 centers and data prospectively collected.
ll patients were considered at high or prohibitive risk of
onventional surgery as assessed by a multidisciplinary team
onsisting in each center of at least 2 interventional cardi-
logists, 2 cardiothoracic surgeons, a cardiac anesthesiolo-
ist, and a cardiologist specializing in imaging. Our present
election algorithm is shown (Fig. 1). Transthoracic or
ransesophageal (in cases of suboptimal echogenicity) echo-
ardiography was employed for annular measurements, with
nd-diastolic measurement from hinge point to hinge point
n the parasternal or mid-esophageal long-axis views. Suit-
bility by annular dimension was based on the criteria for
ach respective device. Invasive angiography and/or multi-
lice computed tomography were used to measure minimal
liofemoral dimension from mid-femoral head proximally; a
raduated pigtail was employed for calibration. The true
inimum dimension was taken as the selection criteria for
uitability; in patients with acceptably large common fem-
ral arteries, dilation of iliac stenoses to gain vascular access
bbreviations
nd Acronyms
AVI  transcatheter aortic
alve implantationas not permitted in the protocol. The proportion of watients suitable for each device by transfemoral approach
as calculated.
dwards suitability. The annular dimension criteria for Ed-
ards Sapien device is 18 to 22 mm for the 23-mm device
nd 21 to 25 mm for the 26-mm device (10). The trans-
emoral access requirements for Edwards Sapien, with the
etroflex 3 system (Edwards Lifesciences), is a minimal
liofemoral dimension of at least 7 mm for the 22-F/23-mm
evice; and a minimal iliofemoral dimension at least 8 mm
or the 24-F/26-mm device. An alternative access approach
or the Edwards system is transapical, which obviates the
eed for large peripheries. It should be noted that the
riginal PARTNER (Placement of AoRTic traNscathetER
alves) trial (11) excluded patients with native aortic annulus
ize 16 mm or 24 mm on the baseline echocardiogram
ut this was estimated by the left ventricular outflow tract.
The imminent next-generation Edwards system (Ed-
ards XT) with Novaflex delivery system is 18-F for the
3-mm device, requiring a minimal iliofemoral dimension
f at least 6 mm and 19-F for the 26-mm device, requiring
minimal iliofemoral dimension of at least 6.5 mm (12).
he proportion of patients from the series suitable for these
evices and access approaches was determined.
edtronic CoreValve suitability. The annular dimension re-
uirement for Medtronic CoreValve is 20 to 23 mm for the
6-mm device and 23 to 27 mm for the 29-mm device (5).
or transfemoral access, the device has 18-F requirements
minimal iliofemoral dimension at least 6 mm). An addi-
ional requirement is that the ascending aorta diameter 40
m distal to the aortic annulus be 40 mm (for the smaller
6-mm inflow valve) and 43 mm (for the larger 29-mm
nflow valve). Alternative approaches for the Medtronic
oreValve device are transaxillary (13,14) and direct
ccess via the ascending aorta (15), which allow implan-
ation in the setting of nonpermissive iliofemoral vessels.
he proportion of patients from the series suitable for
hese approaches for the Medtronic CoreValve device
as determined.
tatistical analyses. The range of patients suitable for a
-device TAVI strategy was compared with that suitable for
ingle-device approaches with Edwards and CoreValve,
espectively, using McNemar paired nominal tests for
ndividual patients in the consecutive series; the addi-
ional range of patients made suitable for TAVI with a
-device approach by alternative access (transapical for
dwards and axillary/direct aortic access for CoreValve)
as compared with that suitable for a 2-device trans-
emoral approach. Averages for continuous data are re-
resented as the mean  SD.
esults
ata were analyzed for 100 consecutive patients. Mean age
as 80.9  7.4 years and mean logistic EuroSCORE
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861European System for Cardiac Operative Risk Evaluation)
8.4  12.7. The distribution of annular dimensions and
inimum lumen diameter of the iliofemoral artery on the
argest side are illustrated in Figures 2 and 3.
Edwards Sapien suitability was 28% for the current
ransfemoral devices, 88% for the Edwards Sapien transapi-
al device, and 78% for the Edwards XT Novaflex trans-
emoral device. Medtronic CoreValve suitability was 84%
or transfemoral and 89% using additional transaxillary and
irect aortic approaches. Notably, the increase in the upper
imit of annular suitability from 24 to 25 mm for the
dwards Sapien system increased the suitability from 20%
o 28% for the transfemoral approach and 74% to 88% for
Figure 1. Case Selection
Suggested case selection algorithm for contemporary 2-device approach to tra
track.” Multiple approaches increase the number of patients anatomically suita
tomography; LVOT  left ventricular outﬂow track.he transapical approach (Table 1). wOf the 12 patients unsuitable for Edwards-based proce-
ures, 8 were suitable for Medtronic CoreValve. Of the 11
atients unsuitable for Medtronic CoreValve–based tech-
iques, 8 were suitable for Edwards. Only 3% of the whole
opulation was anatomically unsuitable for all approaches.
A 2-device strategy increased patients suitable for TAVI
o 97% from 88% for Edwards-based approaches (p 
.004) and from 89% for Medtronic CoreValve–based
pproaches (p  0.008). There were 97% of patients
uitable for TAVI by any approach with either device,
ompared with 92% of patients suitable for a multidevice
ransfemoral approach alone (p  0.063). The 92% of
atients suitable for a multiple device transfemoral approach
eter aortic valve implantation: (blue) ”Edwards track”; (red) ”CoreValve
r at least 1 transcatheter aortic valve implantation approach. CT  computednscath
ble foas significantly greater than the 28% suitable for Edwards
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862apien transfemoral (p  0.001), the 78% suitable for
dwards XT Novaflex transfemoral (p  0.001) and the
4% suitable for the Medtronic CoreValve–based trans-
emoral (p  0.008) approaches.
utcomes in those undergoing TAVI. Of the 100 consecutive
ases assessed, 52 have thus far undergone TAVI. These
atients had a mean age of 82.6  5.8 years and a mean
ogistic EuroSCORE of 21.1  14.6. There was procedural
ailure in 2 cases (3.8%), post-procedural stroke in 1 (1.9%),
nd 30-day mortality in 4 (7.6%). Baseline aortic valve area
as 0.72  0.18 cm2 and increased to 1.75  0.43 cm2 on
re-discharge echocardiogram. No significant post-
rocedural transvalvular aortic regurgitation was seen. Para-
alvular aortic regurgitation of grade 2 or more was seen in
patients (9.6%); this was of grade 3 in 1 and there were no
ases of grade 4 aortic regurgitation seen.
In 3 cases, TAVI was performed in cases anatomically
nsuitable according to selection criteria. In 1 case, a
oreValve device was implanted despite a large proximal
scending thoracic aorta (47 mm) and was uncomplicated.
Figure 2. Aortic Annulus Variation
Distribution of annulus dimension in the population screened; measured on tr
parasternal long-axis view.n a further case, before the availability of the transapical and aransaxillary approaches, a transfemoral CoreValve was im-
lanted with a dottering maneuver despite sub–6-mm diffusely
iseased and calcified iliofemoral vessels (Fig. 4A) and resulted
n acute thrombosis (Fig. 4B) following partial arterial avulsion
n sheath removal; there was no major bleeding and the
hrombus resolved with heparinization without adverse se-
uelae. In the third case, a 23-mm transfemoral Edwards
apien valve was implanted in a patient with a short segment
roximal iliac stenosis (6.7 mm) whereas the remainder of the
liofemoral vasculature was appropriately sized; this was per-
ormed without complication.
iscussion
his study of consecutive patients referred for TAVI dem-
nstrates that with a 2-device strategy, more patients are
natomically suitable for this therapy. This is because the
rincipal limitation for Edwards Sapien (large annular
imension) differs from those for Medtronic CoreValve
small annulus dimension and large proximal ascending
racic echocardiography using hinge point–to–hinge point dimension inansthoortic dimension). Therefore, the use of both devices is
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863omplementary and makes TAVI available for patients at
ither end of anatomical requirements.
It has been recently appreciated that measurements of the
ortic annulus using transthoracic echocardiography, trans-
sophageal echocardiography, and multislice computed to-
ography are similar but not identical, and the method used
as important potential clinical implications for TAVI
Figure 3. Variation in Iliofemoral Dimension
Measurements made using peripheral X-ray angiography. Distribution of minim
femoral arterial access.
Table 1. Unsuitability for Different Devices and Approaches Currently Wide
Reason Unsuitable
Edwards Sapien Transfemoral Edwards
Original PARTNER
Trial Criteria
17–24-mm Annuli
Current IFU Criteria
18–25-mm Annuli
Original PARTN
Trial Criteria
17–24-mm An
Annulus too small 0 0 0
Annulus too large 26 12 26
Peripheries too small 60 60 —
Aorta too large — — —
Total unsuitable 80 72 26
Values are presented as %.IFU instruction for use; PARTNER Placement of AoRTic traNscathetER valves trial.trategy (16). Some operators have used balloon aortic
alvuloplasty to help determine appropriate transcatheter
ortic valve size (17).
The selection constraints imposed by iliofemoral vessel
ize can be minimized by a transfemoral approach using
oth the Medtronic CoreValve 18-F system and the
dwards XT 18-F/19-F Novaflex delivery system. These
en diameter (MLD) of iliofemoral vasculature proximal to preferred site of
ilable
n Transapical
Edwards XT
Transfemoral With
Novaflex Delivery System
CoreValve
Current IFU Criteria
18–25-mm Annuli Transfemoral
Transaxillary
or Direct
Aortic Access
0 0 3 3
12 12 0 0
— 13 6 —
— 0 8 8
12 22 16 11al lumly Ava
Sapie
ER
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864ystems will treat a wide range of patients (84% and 78%,
espectively, in this series). This range is increased further
or the respective devices by use of alternative approaches
89% and 88%, respectively).
It should be noted that with the combination of trans-
emoral devices available, the additional contribution of
lternative access approaches (transapical for the Edwards
apien system and transaxillary/direct aortic access for the
edtronic CoreValve system) is limited. We observed that
2% of cases were suitable for a multidevice transfemoral
pproach and only 5% more cases were afforded treatment
y the addition of other approaches. This supports the
ationale that TAVI should primarily be a catheterization
aboratory-based transfemoral procedure, reserving other
pproaches for a minority. This is not presently the case for
he Edwards Sapien system, which has a greater reliance on
he transapical approach; the imminent reduction in device
rofile via the Novaflex system is likely to dramatically
hange practice (12). Conversely, proponents of the
ransapical approach point to an avoidance of extracardiac
ascular complications (6).
volution of the present mainstream TAVI devices. Both
urrently available transcatheter aortic bioprostheses, Ed-
ards Sapien and Medtronic CoreValve, are evolving their
evices into smaller profiles to treat a wider range of annuli.
he Edwards system miniaturization has been difficult in
iew of the balloon expandable design but is facilitated in
Figure 4. A Complicated Case
Anatomically ”off-label” transfemoral CoreValve implantation via diffusely disea
(B, arrows) was observed, which responded well to conservative managemen
in the absence of other therapeutic alternatives at the time of the procedure,
for hazardous sequelae of suboptimal case selection.art by the change in material of the stent frame from the 2tainless steel of the Edwards Sapien to the cobalt chro-
ium of the Edwards XT. Also, the profile has been further
educed by an innovative Novaflex delivery system (Fig. 5)
omprising a mechanism by which the stented valve is
nitially crimped on the catheter shaft and advanced to the
evel of the balloon in vivo for deployment (12). This has
acilitated the reduction in profile from 22- to 18-F for the
3-mm prosthesis and from 24- to 19-F for the 26-mm
rosthesis. These systems have already been used with
uccess in Canada and Europe and are currently being
valuated in Europe in the PREVAIL (Prevention of
TE After Acute Ischemic Stroke With LMWH Enox-
parin) study. In addition, 20- and 29-mm prostheses are
nder development, but the time frame for these to come
o fruition is unclear (Edwards Lifesciences, March
010).
The Medtronic CoreValve system has a self-expanding
rosthesis with a nitinol stent frame affording a low profile
nd early development of an 18-F system. Interestingly, the
eduction in profile from the 21-F second-generation sys-
em to the 18-F present- (third-) generation system was
acilitated by the replacement of bovine valve leaflets with
hose of porcine pericardial origin (18). There are 31- and
3-mm inflow devices in development that will expand the
ange of annuli to 27 to 29 mm and 18 to 20 mm,
espectively. The company plans to eventually have the 23-
nd 26-mm inflow devices in a 16-F system, and the larger
nd calciﬁed iliofemoral vessels with diameter 6 mm (A). Acute thrombosis
heparinization without adverse sequelae. Although this case was performed
trates the importance of optimal anatomical case selection and the potentialsed a
t with
it illusin the 18-F system (Medtronic Inc., March 2010).
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865ualitative versus quantitative suitability. The creation of
ultiple device sizes with similar access requirements will
ead to the anatomic suitability of patients for both device
ypes. However, qualitative differences will remain between
he systems and will have an impact on clinical suitability.
he tailoring of therapy will be increasingly relevant as more
enters are trained in the implantation of multiple devices.
or instance, the CoreValve device can be rapidly deployed
ithout the need for rapid pacing and transesophageal
chocardiography guidance, and it has a default leaflet
onfiguration that is closed rather than open. This makes it
he therapy of choice in the presence of hemodynamic
nstability.
A severely angulated ascending aorta or arch may favor an
ntegrade (transapical) approach, whereas cases with low
oronary ostia may be more safely treated by the self-
xpanding design with its constrained central portion, pro-
ided the sinuses are not shallow. In contrast, a different
ortic root morphology with shallow coronary sinuses may
Table 2. Next-Generation Devices
Device
Approach(es)
Available BE/SE/Other
EndoLumix* TF BE
Direct Flow† TF Other
Heart Leaﬂet Technologies‡ TF SE
JenaValve§ TA (TF to follow) SE
Ventor Engager (Medtronic Ventor) TA SE
Sadra Lotus¶ TF SE
*EndoLumix Technologies, LLC, Houston, Texas.†Direct FlowMedical, Inc., Santa Rosa, California.‡H
Medical, Inc., Los Gatos, California. Medtronic Inc., Luxembourg City, Luxembourg.
Figure 5. Newer Devices Studied
(A) The Novaﬂex system. This new system facilitates reduction in proﬁle for th
(A, Top) The stented valve is crimped ex vivo onto catheter shaft. (A, Middle)
(A, Bottom) The stented valve is deployed at the level of the aortic annulus. (BE balloon expandable; LVOT left ventricular outflow tract; SE self-expanding; TA transapical; Te better suited to the shorter-frame Edwards Sapien
esign. The use of multiple devices in TAVI centers will
elp to refine this complementary approach, with the
elative strengths of each respective technology tailored to a
articular patient.
ext-generation devices. Other valve companies, such as St.
ude Medical and Sorin, are rapidly developing their TAVI
evices and it remains unclear as to which anatomic dimen-
ions they will target (St. Jude Medical Inc., December
009; Sorin Group, December 2009). A number of start-up
ompanies including Sadra Medical (19), Direct Flow
edical (20), EndoLumix Technology (21), Heart Leaflet
echnologies (22), JenaValve (23), Medtronic Ventor
echnologies (24), and Symetis (25) have developed trans-
emoral devices as small as 14-F and can treat annuli well
eyond the dimensions seen in our study (Table 2). The
almaz-Bailey transcatheter valve promises an even smaller
rofile as low as 10-F, although the exact nature and time
rosthesis Sizes
(mm)
Range of
Annuli Treatable (mm)
French Size of
TF Delivery System
–25, 26–35 20–35 14/16
, 25, 27 19–36 18
, 23, 25 19–25 17
, 23, 25, 27 19–26.6 —
, 26, 29 19–28 mm (LVOT measurement) —
, 27 19–26 18
flet Technologies, Inc.,MapleGrove,Minnesota.§JenaValve Technology,Munich, Germany.¶Sadra
ards XT device to 18- and 19-F for 23- and 26-mm prostheses, respectively.
elivery system facilitates advancement of stented valve onto balloon in vivo.
Medtronic Ventor system, a self-expanding transapical device.P
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866rame for the clinical fruition of this device is unclear.
ndoubtedly, these novel devices will further increase the
ange of patients anatomically suitable but their principal
ontribution will be through an increase in procedural
implicity and safety.
tudy limitations. The study presented has only looked at 3
arameters of anatomic suitability that document the key
natomic inclusion and exclusion criteria. Other factors are
elevant and include excessive femoral calcification and
ortuosity, the severely hypertrophied septum and shallow or
hort aortic sinuses. These are special situations that deserve
ention but, in terms of frequency, are not the principal
natomical limitations of TAVI today.
Our population, although bicentric, represented one
f predominantly Caucasian ethnicity or large non-
aucasians, and populations of different ethnic distribution
ay have a greater reliance on transapical or alternative
pproaches to that of the femoral artery. Indeed, a study
onducted by Schnyder et al. (26) in California suggested
hat there might be a lower incidence of female patients
uitable for a present-day transfemoral TAVI approach,
ith femoral arteries greater than 6 mm in minimal dimen-
ion seen in only 50% of females in their series.
onclusions
n the series presented, 97% of patients were anatomically
uitable for a complementary approach to treatment by
dwards Lifesciences or Medtronic CoreValve devices. The
-device strategy will offer TAVI to significantly more
atients than a single-device service. The future expansion
f device sizes will increase patient suitability for each
ystem, and the variety of access approaches will ensure that
he vast majority of patients can be treated. Having over-
ome anatomic constraints, the evolution of next-generation
evices may best be directed toward procedural simplifica-
ion and safety.
eprint requests and correspondence: Dr. Jan Kovac, Depart-
ent of Cardiology, Glenfield General Hospital, Leicester
E3 9QP, United Kingdom. E-mail: jankovac2@hotmail.com.
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